MA35860B1 - Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a - Google Patents
Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10aInfo
- Publication number
- MA35860B1 MA35860B1 MA37201A MA37201A MA35860B1 MA 35860 B1 MA35860 B1 MA 35860B1 MA 37201 A MA37201 A MA 37201A MA 37201 A MA37201 A MA 37201A MA 35860 B1 MA35860 B1 MA 35860B1
- Authority
- MA
- Morocco
- Prior art keywords
- enzyme inhibitors
- quinoline derivatives
- compounds
- pde10a enzyme
- relates
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title abstract 2
- 239000002532 enzyme inhibitor Substances 0.000 title abstract 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des dérivés de quinoléine de formule (i) qui sont des inhibiteurs d'enzyme pde10a, et en tant que tels sont utiles pour traiter des troubles neurodégénératifs et psychiatriques. En particulier, l'invention concerne des composés qui sont très sélectifs pour pde10 par rapport aux autres sous-type de pde. La présente invention concerne en outre des compositions pharmaceutiques comprenant des composés de l'invention et des procédés de traitement de troubles en utilisant les composés de l'invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201100990 | 2011-12-21 | ||
| PCT/EP2012/076590 WO2013092974A1 (fr) | 2011-12-21 | 2012-12-21 | Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35860B1 true MA35860B1 (fr) | 2014-12-01 |
Family
ID=48667762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37201A MA35860B1 (fr) | 2011-12-21 | 2014-07-11 | Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9216986B1 (fr) |
| EP (1) | EP2794606A1 (fr) |
| JP (1) | JP6073918B2 (fr) |
| KR (1) | KR20140105574A (fr) |
| CN (1) | CN104114554A (fr) |
| AP (1) | AP2014007697A0 (fr) |
| AR (1) | AR089361A1 (fr) |
| AU (1) | AU2012356885B2 (fr) |
| BR (1) | BR112014015192A8 (fr) |
| CA (1) | CA2859702A1 (fr) |
| CL (1) | CL2014001643A1 (fr) |
| CO (1) | CO6990727A2 (fr) |
| CR (1) | CR20140289A (fr) |
| DO (1) | DOP2014000141A (fr) |
| EA (1) | EA028824B1 (fr) |
| EC (1) | ECSP14010000A (fr) |
| GE (1) | GEP201706657B (fr) |
| HK (1) | HK1202861A1 (fr) |
| IL (1) | IL233226A (fr) |
| MA (1) | MA35860B1 (fr) |
| MD (1) | MD20140070A2 (fr) |
| MX (1) | MX348792B (fr) |
| MY (1) | MY165216A (fr) |
| PE (1) | PE20141945A1 (fr) |
| PH (1) | PH12014501434B1 (fr) |
| RU (1) | RU2624440C2 (fr) |
| SG (1) | SG11201403339YA (fr) |
| TN (1) | TN2014000268A1 (fr) |
| TW (1) | TWI570124B (fr) |
| UA (1) | UA111871C2 (fr) |
| WO (1) | WO2013092974A1 (fr) |
| ZA (1) | ZA201404533B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI570124B (zh) | 2011-12-21 | 2017-02-11 | Ｈ 朗德貝克公司 | 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物 |
| AU2013352463B2 (en) * | 2012-11-29 | 2017-06-15 | Sunovion Pharmaceuticals Inc. | Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| US20070105840A1 (en) | 2003-06-30 | 2007-05-10 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| RS20050945A (sr) | 2003-06-30 | 2008-06-05 | Altana Pharma Ag., | Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera |
| EP1651251A4 (fr) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a |
| EP1723134A2 (fr) | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Derives tetrahydroisoquinolinyliques de quinazoline et d'isoquinoline |
| EP1755611A1 (fr) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| CA2578996A1 (fr) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | Derives de 4, 6-dialkoxy-cinnoline substitues en position 4 en tant qu'inhibiteurs de phospodiesterase 10 pour le traitement de syndromes psychiatriques ou neurologiques |
| EP2565191B1 (fr) | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | Dérivés d'acide 4-(indol-7-ylcarbonylaminométhyl)cyclohexanecarboxylique comme antagonistes du récepteur EP4 utilisables pour le traitement de l'insuffisance rénale chronique ou de la néphropathie diabétique |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| CA2765750A1 (fr) | 2009-06-19 | 2010-12-23 | H. Lundbeck A/S | Nouveau derive de phenylimidazole en tant qu'inhibiteur de l'enzyme pde10a |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| JP2011201873A (ja) * | 2010-03-03 | 2011-10-13 | Mitsubishi Tanabe Pharma Corp | 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用 |
| US8969349B2 (en) * | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| TWI570124B (zh) | 2011-12-21 | 2017-02-11 | Ｈ 朗德貝克公司 | 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物 |
-
2012
- 2012-12-20 TW TW101148618A patent/TWI570124B/zh not_active IP Right Cessation
- 2012-12-20 AR ARP120104861A patent/AR089361A1/es unknown
- 2012-12-21 GE GEAP201213526A patent/GEP201706657B/en unknown
- 2012-12-21 MY MYPI2014001793A patent/MY165216A/en unknown
- 2012-12-21 UA UAA201407913A patent/UA111871C2/uk unknown
- 2012-12-21 EA EA201491152A patent/EA028824B1/ru not_active IP Right Cessation
- 2012-12-21 SG SG11201403339YA patent/SG11201403339YA/en unknown
- 2012-12-21 KR KR1020147019800A patent/KR20140105574A/ko not_active Ceased
- 2012-12-21 WO PCT/EP2012/076590 patent/WO2013092974A1/fr not_active Ceased
- 2012-12-21 US US14/305,736 patent/US9216986B1/en not_active Expired - Fee Related
- 2012-12-21 AP AP2014007697A patent/AP2014007697A0/xx unknown
- 2012-12-21 AU AU2012356885A patent/AU2012356885B2/en not_active Ceased
- 2012-12-21 MX MX2014007409A patent/MX348792B/es active IP Right Grant
- 2012-12-21 CA CA2859702A patent/CA2859702A1/fr not_active Abandoned
- 2012-12-21 BR BR112014015192A patent/BR112014015192A8/pt active Search and Examination
- 2012-12-21 EP EP12815695.7A patent/EP2794606A1/fr not_active Withdrawn
- 2012-12-21 PE PE2014000989A patent/PE20141945A1/es not_active Application Discontinuation
- 2012-12-21 HK HK15103345.9A patent/HK1202861A1/xx unknown
- 2012-12-21 JP JP2014548059A patent/JP6073918B2/ja not_active Expired - Fee Related
- 2012-12-21 RU RU2014127984A patent/RU2624440C2/ru not_active IP Right Cessation
- 2012-12-21 CN CN201280069658.7A patent/CN104114554A/zh active Pending
- 2012-12-21 MD MDA20140070A patent/MD20140070A2/ro not_active Application Discontinuation
-
2014
- 2014-06-16 TN TNP2014000268A patent/TN2014000268A1/en unknown
- 2014-06-17 DO DO2014000141A patent/DOP2014000141A/es unknown
- 2014-06-17 CR CR20140289A patent/CR20140289A/es unknown
- 2014-06-18 IL IL233226A patent/IL233226A/en not_active IP Right Cessation
- 2014-06-19 CL CL2014001643A patent/CL2014001643A1/es unknown
- 2014-06-20 ZA ZA2014/04533A patent/ZA201404533B/en unknown
- 2014-06-20 CO CO14134658A patent/CO6990727A2/es unknown
- 2014-06-20 PH PH12014501434A patent/PH12014501434B1/en unknown
- 2014-07-11 MA MA37201A patent/MA35860B1/fr unknown
- 2014-07-18 EC ECIEPI201410000A patent/ECSP14010000A/es unknown
-
2015
- 2015-11-13 US US14/940,272 patent/US9801878B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
| MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
| MA35096B1 (fr) | Cyclopropylamines en tant qu'inhibiteurs de lsd1 | |
| MA37958B1 (fr) | Pde9i ayant un squelette imidazo pyrazinone | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
| MA41251B1 (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| MA33119B1 (fr) | Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase | |
| MA37798B1 (fr) | 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes | |
| MA34797B1 (fr) | Hétéroaryles et leurs utilisations | |
| MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
| SG195100A1 (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors | |
| MA34844B1 (fr) | Derives de (1,2,4) triazolo[4,3-a]quinoxaline comme inhibiteurs de phosphodiestérases | |
| UA111198C2 (uk) | Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази | |
| MA42811B1 (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA38076A1 (fr) | Dérivés d'oxazolidin-2-one-pyrimidine | |
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| EA201001481A1 (ru) | Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4 | |
| MA38678A1 (fr) | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués | |
| MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| MA35860B1 (fr) | Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a | |
| MA45367B1 (fr) | Inhibiteurs de la tyrosine kinase | |
| MA37836B1 (fr) | Antagonistes du récepteur 5-ht3 | |
| MA35167B1 (fr) | Dérivés pyrazole utiles comme inhibiteurs de l'aldostérone synthase | |
| MA34198B1 (fr) | Dérivés de chroménone convenant comme antagonistes trpv3 |